SCHEMBL2368757

SCHEMBL2368757

Cc1ccc(-c2csc3ncn[c]c23)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
ALOX12 P18054 1/20 0.47
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
ROCK2 O75116 1/20 0.39
RPS6KA5 O75582 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5790076 0.80 SMN1; SMN2 (0.37) LMNAKMT2AMEN1SMN1; SMN2POLB
SCHEMBL2369510 0.78 SMN1; SMN2 (0.52) LMNAKMT2AMEN1CSNK2A2CSNK2B
SCHEMBL2369844 0.78 SMN1; SMN2 (0.52) LMNAKMT2AMEN1CSNK2A2CSNK2B
SCHEMBL2369061 0.77 FGFR1 (0.50) LMNACSNK2A2CSNK2BCSNK2A1SMN1; SMN2
SCHEMBL2369522 0.77 MAPT (0.38) LMNAKMT2AMEN1SMN1; SMN2PRKD3
SCHEMBL5788742 0.77 MAPT (0.56) LMNAKMT2AMEN1POLBFGFR1
SCHEMBL2368088 0.76 HTT (0.45) KMT2ASMN1; SMN2PRKD3MAP4K4ABL1
SCHEMBL2368766 0.76 MITF (0.44) LMNAKMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL5803878 0.76 HTT (0.47) LMNAKMT2AMEN1SMN1; SMN2POLB
SCHEMBL855588 0.74 IRAK4 (0.33) LMNAPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885ALOX12 1347/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.